维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

8篇 您的检索式：作者名="Veraar"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	CD8 + T cells produce the che-mokine CXCL10 in response to CD27/CD70 costimulation to promotegeneration of the CD8 + effector T cell pool 显示文摘	Peperzak V Veraar EA Xiao Y	2013	Immunol2013，191，6：	1
	2	Preeclampsia Is Characterized by Placental Complement Dysregulation.显示文摘	Aletta Buurma Danielle Cohen Kimberley Veraar Dorrith Schonkeren Frans H. Claas Jan A. Bruijn Kitty W. Bloemenkamp Hans J. Baelde	2012	Hypertension2012，，5：	1
	3	Preeclampsia is character- ized by placental complement dysregulation显示文摘	Buurma A Cohen D Veraar K	2012	Hypertension2012，60，5：	1
	4	Preeclampsia is characterized by placental complement dysregulation 显示文摘	Buurma A Cohen D Veraar K	2012	Hypertension2012，60，5：	1
	5	Preeclampsia is characterized by placental complement dysregulation显示文摘	Buurma A Cohen D Veraar K	2012	Hypertension2012，60，5：	1
	6	Preeclampsia is character- ized by placental complement dysregulation 显示文摘	Buurma A Cohen D Veraar K	2012	Hypertension2012，60，5：	1
	7	Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular traffi cking with MHC class II molecules显示文摘	Keller A M Groothuis T A Veraar E A	2007	Proc Natl Acad Sci USA2007，104，：	1
	8	Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase Ⅱ trial EXACT显示文摘Objective: Advances in high-throughput genomic profiling and the development of new targeted therapies improve patient's survival. In gastrointestinal(GI) malignancies, the concept of personalized medicine(PM) was not investigated so far. The aim of this prospective study was to evaluate the efficacy of a personalized treatment in GI patients who failed standard treatment.Methods: Out of the original prospective clinical phase Ⅱ EXACT trial, 21(38%) GI cancer patients who had no further treatment options were identified. A molecular profile(MP) via a 50 gene next generation sequencing(NGS) panel in combination with immunohistochemistry(IHC) was conducted using real-time biopsy tumor material. Results were discussed by a multidisciplinary team(MDT) to translate the individual MP in an experimental treatment.Results: Of the 55 patients originally included in the EXACT trial, 21(38%) suffered from GI malignancies.The final analysis showed that 15(71%) patients had experienced a longer progression-free survival(PFS) upon experimental targeted treatment(124 d, quartiles 70/193 d), when compared with the PFS achieved by the previous conventional therapy(62 d, quartiles 55/83 d)(P=0.014). Thirteen(62%) patients receiving targeted treatment experienced a disease control according to Response Evaluation Criteria in Solid Tumors(RECIST). Median overall survival(OS) from the start of experimental therapy to time of censoring or death was 193 d(quartiles115/374 d).Conclusions: PM was not investigated in GI malignancies so far in a prospective trial. This study shows that treatment based on real-time molecular tumor profiling led to a superior clinical benefit, and survival as well as response was significantly improved when compared with previous standard medications.	Matthias Unseld Robert Mader Lukas Baumann Clarence Veraar Fritz Wrba Fredrik Waneck Markus Kieler Daniela Bianconi Walter Berger Maria Sibilia Leonhard Miillauer Christoph Zielinski Gerald W. Prager	2018	Chinese Journal of Cancer Research2018，30，5：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费